Ablynx announces collaboration with Centocor

13-Jan-2006

Ablynx has signed a collaboration agreement with Centocor Research and Development, Inc. Under the terms of the collaboration, the companies will perform joint research funded by Centocor. Applying the unique properties of Nanobodies, the two companies will work jointly on novel approaches for administration and delivery of Nanobody based therapeutics. The financial terms of the collaboration are not disclosed.

Nanobodies are a novel class of therapeutic proteins that combine the beneficial features of conventional antibodies with desirable properties of small molecule drugs. Nanobodies have the affinity and selectivity of conventional antibodies yet are only a fraction of their size. Because of their unique structure and high stability, Nanobodies can address target opportunities that are beyond the reach of conventional antibodies.

Other news from the department business & finance

Most read news

More news from our other portals

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Last viewed contents

Cystic Fibrosis Foundation - Bethesda, USA

Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize

Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize

New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future

New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe

Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

UF study strengthens concerns about long-term use of certain painkillers

Scientists at Almac and Queen’s University Belfast discover novel approach to treat cancer patients.

Restoring chemotherapy sensitivity by boosting microRNA levels

Restoring chemotherapy sensitivity by boosting microRNA levels

Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer

Centocor, Inc. - Horsham, USA

Centocor, Inc. - Horsham, USA

Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines Without the Destruction of Embryos - Breakthrough Approach Improves Efficiency to Levels Reported in the Conventional Stem Cell Derivation Techniques